Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer (PrTK03)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2016 by Advantagene, Inc.
Sponsor:
Information provided by (Responsible Party):
Advantagene, Inc.
ClinicalTrials.gov Identifier:
NCT01436968
First received: September 19, 2011
Last updated: November 2, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)